Format

Send to

Choose Destination
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.

Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Author information

1
Department of General Surgery, The First Affiliated Hospital, Dalian Medical University Dalian, China.
2
Department of Oncology, The First Affiliated Hospital, Dalian Medical University Dalian, China.
3
Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering Dalian, China.

Abstract

Nek2 is a serine/threonine kinase that has a critical role in mitosis during the cell division process. Despite its importance in centrosome regulation and spindle formation, no direct binders are reported between human pancreatic cancer and Nek2 protein. Our aim in studying Nek2 expression and survival in PDA patients is to determine whether Nek2 is a valuable prognostic factor in PDA tumorigenesis. We found that Nek2 mRNA was elevated in PDA tissues. A high level of expression of Nek2 was significantly correlated with histological differentiation (P=0.042), lymph node metastasis (P=0.003) and tumor stage (P=0.001). Patients with a high Nek2 expression had a significantly worse overall survival (OS) than those patients with low Nek2 expression (P=0.002). Univariate and multivariate analysis revealed that high expression of Nek2 could serve as an independent predictor of poor prognosis. These results indicate that Nek2 could be a promising prognostic molecular marker and an attractive therapeutic target for PDA.

KEYWORDS:

Nek2; pancreatic ductal adenocarcinoma; prognosis

PMID:
24966957
PMCID:
PMC4069945
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center